Printer Friendly

HEALTHWATCH ANNOUNCES METAMED 510(k) FILING

 BROOMFIELD, Colo., Oct. 21 /PRNewswire/ -- HealthWatch Inc. (NASDAQ: HEAL) today announced it has filed an application with the U.S. Food and Drug Administration for permission to market its IV Controller. The filing of the 510(k) application is the first step toward introducing the revolutionary IV instrumentation to the United States marketplace.
 The IV Controller was acquired with METAMED Inc. last month in a merger transaction completed on Sept. 13, 1993. METAMED developed and patented a unique product for intravenous drug delivery. METAMED products will allow the healthcare provider an option for its IV instrumentation not currently offered in today's marketplace. The METAMED products will not require the use of expensive, proprietary IV sets and will be substantially lower cost per use than existing IV instrumentation systems.
 Instruments for controlling the delivery of intravenous solutions and drugs were introduced into the market in the early 1970s. They have evolved into sophisticated, computer-controlled systems which improve the safety and effectiveness of IV therapy in the hospital and in home healthcare. The market for IV products in the United States is considered to be in excess of $800 million. Most IV instruments on the market require the use of dedicated, proprietary IV sets which cost the user as much as four times the price of a "basic" IV set. The METAMED product for which the 510(k) was filed is unique in that the instrument utilizes a patent design which allows the instrument to work with virtually any IV set including the "basic" lower cost IV sets sold by the major IV set manufactures such as Baxter and Abbott.
 In making the announcement, John D. Greenbaum, president and chief executive officer of HealthWatch Inc., stated, "HealthWatch is looking forward to the approval of this application and believes the device will have a major market impact. The era of high cost IV therapy is expecting a healthy demand for product. We also believe that countries with emerging economies will now be able to afford the improved safety of instrumented IV lines by eliminating the expense of the proprietary IV set."
 Based in Broomfield, HealthWatch is a developer, manufacturer, and distributor of medical instrumentation used in cardiovascular diagnosis, vascular diagnosis, and infusion therapy.
 -0- 10/21/93
 /CONTACT: Sanford Schwartz or John D. Greenbaum, 303-465-2000/
 (HEAL)


CO: HealthWatch Inc. ST: Colorado IN: MTC SU:

MF-LS -- LA006 -- 5054 10/21/93 10:07 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 21, 1993
Words:400
Previous Article:FREMONT FINANCIAL PROVIDES $8 MILLION LINE OF CREDIT FOR COMMERCIAL SPORT FISHING YACHT MANUFACTURER
Next Article:MOCON ANNOUNCES SALES AND EARNINGS FOR THIRD QUARTER
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters